Decreased sensitivity of several anticancer drugs in TMEPAI knockout triple-negative breast cancer cells

  • Bantari Wisynu Kusuma Wardhani Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Meidi Utami Puteri Medical Science Master Program, Graduate School of Comprehensive Human Science, University of Tsukuba, Ibaraki, Japan
  • Yukihide Watanabe Department of Experimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
  • Melva Louisa Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Rianto Setiabudy Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Mitsuyasu Kato Department of Experimental Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
DOI: https://doi.org/10.13181/mji.v28i2.2687
Keywords: BCRP, MRP1, P-glycoprotein, TMEPAI, triple-negative breast cancer cell
Abstract viewed: 865 times
PDF downloaded: 786 times
HTML downloaded: 124 times
EPUB downloaded: 290 times

Abstract

BACKGROUND Transmembrane prostate androgen-induced protein (TMEPAI) was reported to be highly amplified in the majority of patients with triple-negative breast cancer (TNBC). TMEPAI is related to poorer prognosis, limited treatment options, and prone to drug resistance compared with other proteins. One of the established markers to determine cancer resistance to drugs is the increased expression levels of drug efflux transporters. However, the role of TMEPAI in cancer resistance to drugs has not been elucidated. This study was aimed to investigate whether TMEPAI participates in cancer resistance to drugs by regulating drug efflux transporters.

METHODS TMEPAI knockout (KO) cells were previously developed from a TNBC cell line, Hs578T (wild-type/WT), using a CRISPR-Cas9 system. The expression levels of drug efflux transporters were determined in Hs578T-KO and Hs578-WT by quantitative reverse transcriptase polymerase chain reaction. Cytotoxic concentration 50% (CC50) of several anticancer drugs (doxorubicin, cisplatin, and paclitaxel) were determined in the two cell lines via 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay.

RESULTS The results showed that the mRNA expression of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) was significantly increased in Hs578T-KO compared with that in Hs578T-WT cells. CC50 of several anticancer drugs investigated (doxorubicin, paclitaxel, and cisplatin) in Hs578T-KO cells was higher than that in Hs678-WT.

CONCLUSIONS TMEPAI participated in the regulation of mRNA expression levels in drug efflux transporters (P-gp, BCRP, and multidrug resistance-associated protein 1). Further studies are necessary to confirm whether this finding might be dependent on the development of cancer cell sensitivity to anticancer agents.

References

  1. Foulkes WD, Smith IE, Reis-Fielho JS. Triple negative breast cancer. N Eng J Med. 2010;363(20):1938-48. https://doi.org/10.1056/NEJMra1001389

  2. Singha PK, Pandeswara S, Geng H, Lan R, Venkatachalam MA, Saikumar P. TGF-β induced TMEPAI/PMEPA1 inhibits canonical Smad signaling through R-Smad sequestration and promotes non-canonical PI3K/Akt signaling by reducing PTEN in triple negative breast cancer. Genes Cancer. 2014;5(9-10):320-36. https://doi.org/10.18632/genesandcancer.30

  3. Krishnamurthy S, Poornima R, Challa VR, Goud YG. Triple negative breast cancer-our experience and review. Indian J Surg Oncol. 2012:3(1):12-6. https://doi.org/10.1007/s13193-012-0138-2

  4. Ng CH, Pathy NB, Taib NA, Teh YC, Mun KS, Amiruddin A, et al. Comparison of breast cancer in Indonesia and Malaysia-a clinico-pathological study between Dharmais Cancer Center Jakarta and University Malaya Medical Center, Kuala Lumpur. Asian Pac J Cancer Prev. 2011;12(11):2943-6.

  5. O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, et al. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin. 2015;3:257-75. https://doi.org/10.1016/j.bbacli.2015.03.003

  6. Xu LL, Shanmugam N, Segawa T, Sesterhenn IA, McLeod DG, Moul JW, et al. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics. 2000;66(3):257-63. https://doi.org/10.1006/geno.2000.6214

  7. National Center for Biotechnology Information. NCBI[Internet]. Bethesda MD USA: US National Library of Medicine; 2016 [cited 2016 Oct 23]. Available from: https://www.ncbi.nlm.nih.gov/gene/56937.

  8. Giannini G, Ambrosini MI, Di Marcotullio L, Cerignoli F, Zani M, MacKay AR, et al. EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer. Mol Carcinog. 2003;38(4):188-200. https://doi.org/10.1002/mc.10162

  9. Brunschwig EB, Wilson K, Mack D, Dawson D, Lawrence E, Willson JK, et al. PMEPA1, a transforming growth factor-b-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. Cancer Res. 2003;63(7):1568-75.

  10. Vo Nguyen TT, Watanabe Y, Shiba A, Noguchi M, Itoh S, Kato M. TMEPAI/PMEPA1 enhances tumorigenic activities in lung cancer cells. Cancer Sci. 2014;105(3):334-41. https://doi.org/10.1111/cas.12355

  11. Watanabe Y, Itoh S, Goto T, Ohnishi E, Inamitsu M, Itoh F, et al. TMEPAI, a transmembrane TGF-β-inducible protein, sequesters Smad proteins from active participation in TGF-β signaling. Mol Cell. 2010;37(1):123-34. https://doi.org/10.1016/j.molcel.2009.10.028

  12. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725-31. https://doi.org/10.1007/s10549-009-0674-9

  13. Wardhani BW, Puteri MU, Watanabe Y, Louisa M, Setiabudy R, Kato M. Knock-out transmembrane prostate androgen-induced protein gene suppressed triple-negative breast cancer cell proliferation. Med J Indones. 2017;26(3):178-82. https://doi.org/10.13181/mji.v26i3.1823

  14. Hu Y, He K, Wang D, Yuan X, Liu Y, Ji H, et al. TMEPAI regulates EMT in lung cancer cells by modulating the ROS and IRS-1 signaling pathways. Carcinogenesis. 2013;34(8):1764-72. https://doi.org/10.1093/carcin/bgt132

  15. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525-30. https://doi.org/10.1038/nature16064

  16. Wardhani BW, Puteri MU, Watanabe Y, Louisa M, Setiabudy R, Kato M. TMEPAI genome editing in triple negative breast cancer cells. Med J Indones. 2017;26:14-8. https://doi.org/10.13181/mji.v26i1.1871

  17. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human tripple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67. https://doi.org/10.1172/JCI45014

  18. Chen WC, Lai Y, Lin YC, Ma JW, Huang LF, Yang NS, et al. Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/Akt signaling pathways in triple-negative breast cancer cells. J Agric Food Chem. 2013;61(48):11817-24. https://doi.org/10.1021/jf404092f

  19. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440-6. https://doi.org/10.1097/FPC.0b013e32833ffb56

  20. Weaver BA. How taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25(18):2677-81. https://doi.org/10.1091/mbc.e14-04-0916

  21. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanism of action. Eur J Pharmacol. 2014;740:364-78. https://doi.org/10.1016/j.ejphar.2014.07.025

  22. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275-92. https://doi.org/10.1002/path.1706

  23. Oh KT, Baik HJ, Lee AH, Oh YT, Youn YS, Lee ES. The reversal of drug-resistance in tumor using a drug-carrying nanoparticular system. Int J Mol Sci. 2009;10(9):3776-92. https://doi.org/10.3390/ijms10093776

  24. Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, de Lourdes Bastos M, et al. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 2015;149:1-123. https://doi.org/10.1016/j.pharmthera.2014.11.013

  25. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123(3):1348-58. https://doi.org/10.1172/JCI65416

  26. Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene. 2010;29(43):5785-95. https://doi.org/10.1038/onc.2010.303

Published
2019-08-09
How to Cite
1.
Wardhani BWK, Puteri MU, Watanabe Y, Louisa M, Setiabudy R, Kato M. Decreased sensitivity of several anticancer drugs in TMEPAI knockout triple-negative breast cancer cells. Med J Indones [Internet]. 2019Aug.9 [cited 2024Apr.24];28(2):110-5. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/2687
Issue
Vol. 28 No. 2 (2019): June
Section
Basic Medical Research

Copyright (c) 2019 Bantari WK Wardhani, Meidi U Puteri, Yukihide Watanabe, Melva Louisa, Rianto Setiabudy, Mitsuyasu Kato

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.

Most read articles by the same author(s)